BioAtla (NASDAQ:BCAB) Rating Lowered to Market Perform at Citizens Jmp

BioAtla (NASDAQ:BCAB) was downgraded by equities research analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, Marketbeat Ratings reports.

Separately, Wall Street Zen raised shares of BioAtla from a “sell” rating to a “hold” rating in a research report on Friday, June 6th.

BioAtla Trading Down 7.2%

Shares of BioAtla stock opened at $0.36 on Wednesday. The company’s fifty day simple moving average is $0.39 and its two-hundred day simple moving average is $0.39. The company has a market cap of $21.27 million, a P/E ratio of -0.33 and a beta of 0.90. BioAtla has a 12-month low of $0.24 and a 12-month high of $2.53.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). Analysts predict that BioAtla will post -1.46 EPS for the current fiscal year.

Institutional Trading of BioAtla

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in shares of BioAtla by 62.2% during the 4th quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock valued at $490,000 after buying an additional 318,196 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of BioAtla by 84.0% during the 4th quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after buying an additional 61,725 shares in the last quarter. Jane Street Group LLC boosted its stake in BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock worth $88,000 after purchasing an additional 100,204 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in BioAtla in the 4th quarter worth about $383,000. Finally, Boxer Capital Management LLC bought a new position in BioAtla in the 4th quarter worth about $406,000. Institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.